Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | — | — | — | 2 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 2 | — | — | — | 2 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | — | 1 |
Drug common name | SODELGLITAZAR |
INN | sodelglitazar |
Description | Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.
|
Classification | Small molecule |
Drug class | peroxisome proliferator activiating receptor (PPAR) agonists (not thiazolidene derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O |
PDB | — |
CAS-ID | 447406-78-2 |
RxCUI | — |
ChEMBL ID | CHEMBL2104984 |
ChEBI ID | — |
PubChem CID | 9805950 |
DrugBank | — |
UNII ID | 6G973E04VI (ChemIDplus, GSRS) |